Across TCGA pan-cancer cohorts, DOK7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DOK7 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher DOK7 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated DOK7 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM, UCS, and LUAD are the cancer types where DOK7 Mutation most reproducibly stratifies survival.